Sonia Quaratino

Ichnos Sciences, Inc. operates as a biotechnology company. It provides curative therapies that extend human life. The company was founded in 2019 and is headquartered in Paramus, NJ.

The General Medical Council provides business support services. The non-profit company is based in London, UK. The CEO of the British company is Charlie Massey.

American Association for Cancer Research prints and publishes scientific journals including clinical cancer research, molecular cancer therapeutics, molecular cancer research, cancer epidemiology, and biomarkers and prevention. The company was founded on May 7, 1907 and is headquartered in Philadelphia, PA.

The American Society of Clinical Oncology is a non-profit organization founded in 1964 with the overarching goals of improving cancer care and prevention. More than 27,000 oncology practitioners belong to ASCO, representing all oncology disciplines and subspecialties. Members include physicians and health-care professionals in all levels of the practice of oncology. American Society of Clinical Oncology is the world’s leading professional organization representing physicians who treat people with cancer. ASCO’s members set the standard for patient care worldwide and lead the way in carrying out clinical research aimed at improving the prevention, diagnosis, and treatment of cancer. ASCO's efforts are also directed toward advocating for policies that provide access to high-quality care for all patients with cancer and at supporting the increased funding for clinical and translational research.

Engitix Ltd. is a preclinical stage biopharma British company that is developing breakthrough therapies for fibrosis and solid tumors using its patient-centric human extracellular matrix drug discovery platform. The company has drug discovery partnerships with Dompe Farmaceutici and Takeda for advanced fibrotic liver diseases and fibrostenotic inflammatory bowel disease. Engitix was established in 2016 to commercialize research from the Institute for Liver and Digestive Health at University College London. The company is headquartered in WestWorks, London, UK. Giuseppe Mazza and Massimo Pinzani founded the company, and Giuseppe Mazza has been the CEO since 2016.

Georgiamune, Inc. is a clinical stage biotechnology company that focuses on reprogramming immune signaling pathways to redirect the immune system to fight diseases. The company is based in Silver Spring, MD. The company has designed unique approaches to re-establish immune balance, and its scientific discoveries have led to pioneering immunotherapies targeting high unmet needs. Georgiamune's lead program, Gim-122, is a first-in-class, dual-functioning monoclonal antibody designed to overcome immune therapy resistance in cancer patients. In addition to its lead program, the company is advancing a pipeline of first-in-class therapies for cancer and autoimmune diseases. The company was founded by Samir N. Khleif, a world-renowned medical oncologist and researcher in the field of immunology and cancer, based on discoveries in his lab on novel mechanisms to modulate immune response. Samir N. Khleif has been the CEO since incorporation.